These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 30158203)

  • 1. Assessment of industry data on pulmonary and immunosuppressive effects of IQOS.
    Moazed F; Chun L; Matthay MA; Calfee CS; Gotts J
    Tob Control; 2018 Nov; 27(Suppl 1):s20-s25. PubMed ID: 30158203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IQOS: examination of Philip Morris International's claim of reduced exposure.
    St Helen G; Jacob Iii P; Nardone N; Benowitz NL
    Tob Control; 2018 Nov; 27(Suppl 1):s30-s36. PubMed ID: 30158205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revolution or redux? Assessing IQOS through a precursor product.
    Elias J; Dutra LM; St Helen G; Ling PM
    Tob Control; 2018 Nov; 27(Suppl 1):s102-s110. PubMed ID: 30305324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling the impact of a new tobacco product: review of Philip Morris International's Population Health Impact Model as applied to the IQOS heated tobacco product.
    Max WB; Sung HY; Lightwood J; Wang Y; Yao T
    Tob Control; 2018 Nov; 27(Suppl 1):s82-s86. PubMed ID: 30275170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PMI's own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes.
    Glantz SA
    Tob Control; 2018 Nov; 27(Suppl 1):s9-s12. PubMed ID: 30131374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IQOS labelling will mislead consumers.
    McKelvey K; Popova L; Kim M; Lempert LK; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
    Tob Control; 2018 Nov; 27(Suppl 1):s48-s54. PubMed ID: 30158208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial function is impaired by aerosol from a single IQOS HeatStick to the same extent as by cigarette smoke.
    Nabavizadeh P; Liu J; Havel CM; Ibrahim S; Derakhshandeh R; Jacob Iii P; Springer ML
    Tob Control; 2018 Nov; 27(Suppl 1):s13-s19. PubMed ID: 30206183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA's reduced exposure marketing order for IQOS: why it is not a reliable global model.
    Lempert LK; Bialous S; Glantz S
    Tob Control; 2022 Aug; 31(e1):e83-e87. PubMed ID: 33811155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heated tobacco products likely appeal to adolescents and young adults.
    McKelvey K; Popova L; Kim M; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
    Tob Control; 2018 Nov; 27(Suppl 1):s41-s47. PubMed ID: 30352843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Awareness, experience and prevalence of heated tobacco product, IQOS, among young Korean adults.
    Kim J; Yu H; Lee S; Paek YJ
    Tob Control; 2018 Nov; 27(Suppl 1):s74-s77. PubMed ID: 30158210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Creating a market for IQOS: analysis of Philip Morris' strategy to introduce heated tobacco products to the Australian consumer market.
    Watts C; Burton S; Freeman B
    Tob Control; 2022 May; 31(3):458-463. PubMed ID: 33191270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Free-Base and Total Nicotine, Reactive Oxygen Species, and Carbonyl Emissions From IQOS, a Heated Tobacco Product.
    Salman R; Talih S; El-Hage R; Haddad C; Karaoghlanian N; El-Hellani A; Saliba NA; Shihadeh A
    Nicotine Tob Res; 2019 Aug; 21(9):1285-1288. PubMed ID: 30476301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Informing iQOS Regulations in the United States: A Synthesis of What We Know.
    Berg CJ; Bar-Zeev Y; Levine H
    Sage Open; 2020; 10(1):. PubMed ID: 32719733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IQOS point-of-sale marketing strategies in Israel: a pilot study.
    Bar-Zeev Y; Levine H; Rubinstein G; Khateb I; Berg CJ
    Isr J Health Policy Res; 2019 Jan; 8(1):11. PubMed ID: 30642383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. United States Food and Drug Administration's authorization of reduced exposure claims for IQOS
    Eckford R; Severini G; Sebrié EM; Muggli ME; Beem A; Rosen D; Crosbie E
    Rev Panam Salud Publica; 2022; 46():e155. PubMed ID: 36245905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How Media Stories in Low- and Middle-Income Countries Discussed the U.S. Food and Drug Administration's Modified Risk Tobacco Product Order for IQOS.
    Robichaud MO; Puryear T; Cohen JE; Kennedy RD
    Nicotine Tob Res; 2023 Aug; 25(10):1659-1666. PubMed ID: 37310968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Light and mild redux: heated tobacco products' reduced exposure claims are likely to be misunderstood as reduced risk claims.
    Popova L; Lempert LK; Glantz SA
    Tob Control; 2018 Nov; 27(Suppl 1):s87-s95. PubMed ID: 30209208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving IQOS packaging designs change perceptions of product appeal, uniqueness, quality and safety: a randomised experiment, 2018, USA.
    Lee JGL; Blanchflower TM; O'Brien KF; Averett PE; Cofie LE; Gregory KR
    Tob Control; 2019 Aug; 28(e1):e52-e55. PubMed ID: 31164489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IQOS
    Adriaens K; Gucht DV; Baeyens F
    Int J Environ Res Public Health; 2018 Dec; 15(12):. PubMed ID: 30567400
    [No Abstract]   [Full Text] [Related]  

  • 20. Factors that influence smokers' and ex-smokers' use of IQOS: a qualitative study of IQOS users and ex-users in the UK.
    Tompkins CNE; Burnley A; McNeill A; Hitchman SC
    Tob Control; 2021 Jan; 30(1):16-23. PubMed ID: 31941822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.